PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of PBF-1129 in combination with
nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent)
or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies,
such as PBF-1129 and nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread.